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Phenanthriplatin, that is, (SP-4-3)-diamminechlorido(phenanthridine)platinum(II) nitrate, an effective antitumor cationic Pt(II)
complex, was loaded on negatively charged dextran sulfate (DS) as a model vector for drug delivery via electrostatic interactions.
The free complex and the corresponding conjugate withDS were tested on two standard human tumor cell lines, namely, ovarian
A2780 and colon HCT 116, and on several malignant pleural mesothelioma cell lines (namely, epithelioid BR95, mixed/biphasic
MG06, sarcomatoid MM98, and sarcomatoid cisplatin-resistant MM98R). The in vitro results suggest that the conjugate releases
the active metabolite phenanthriplatin with a biphasic fashion. In these experimental conditions, the conjugate is slightly less active
than free phenanthriplatin; but both exhibited antiproliferative potency higher than the reference metallodrug cisplatin and were
able to overcome the acquired cisplatin chemoresistance in MM98R cells.
1. Introduction
Cisplatin and its congeners (carboplatin and oxaliplatin)
occupy an eminent position in cancer chemotherapy. Unfor-
tunately, their nonspecific targeting and poor delivery cause
heavy side effects. For these reasons, optimal delivery of
cytotoxic Pt(II) agents is of paramount importance to widen
their therapeutic index.
The attachment of drugs to macromolecular carriers sig-
nificantly alters the physicochemical properties of the result-
ing conjugates, prolonging their plasma half-life, and, most
notably, takes advantage of the Enhanced Permeability and
Retention (EPR) effect. This effect, described in the 1980s by
Maeda and coworkers, relies on the fact that newly formed
tumor vessels are often incompletely organized. The vascular
endothelium in tumors proliferates rapidly and has a higher
number of fenestrations and open junctions than the normal
vessels. Moreover, the lack of a functional lymphatic network
prevents efficient removal of excess fluid from solid tumor
tissue. The combination of these two effects makes tumors
hyperpermeable to the circulating macromolecules, which
can extravasate and accumulate in the tumor tissue where
they are retained for long periods [1]. The ability to exploit
the physiopathologic differences between cancer and normal
cells/tissues is at the basis of such a strategy (drug targeting
and delivery, DTD).
In the field of Pt-based antitumor drugs, nanosized
carriers have emerged in the past few decades as an important
way to decrease the side effects of cisplatin and its con-
geners, maintaining intact their cancer killing ability. In par-
ticular, two N-(2-hydroxypropyl)methacrylamide (HPMA)
copolymer conjugates containing a cisplatin-like “Pt(NH
3
)
2
”
or an oxaliplatin-like “Pt(cyclohexane-1R,2R-diamine)” unit
(AP5280 and AP5346 or ProLindac, resp.) entered clinical
development [2]. In this context, several nanoparticles (NPs)
carrying Pt(II)-complexes are worthy of mention, since these
drug candidates are currently under clinical trials (Aro-
platin in phase II, Lipoplatin in phase II/III, Lipoxal, and
LiPlaCis in phase I) [3].
Premature detachment of the cytotoxic payload in the
bloodstreammust be avoided and the drug should be released
in tumor cells in response to the microenvironment (e.g.,
pH or redox potential). In most cases the vector is cova-
lently bound to the drug via a carefully designed spacer,
but also noncovalent interactions (i.e., hydrogen bonding
or hydrophobic or ionic interactions) have been employed
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Figure 1: Sketch of the ionic complexes [Pt(Am)Cl(NH
3
)
2
]+ (Am = pyridine, 1, quinoline, 2, and phenanthridine, 3) as nitrate derivatives
and of dextran sulfate (DS).
[4]. Both approaches offer advantages and disadvantages:
covalent linkers need an accurate design of the cleavable arm
but the release is generally more tunable; on the contrary,
noncovalent interactions are immediately operating, but
drugs can be prematurely and randomly released by ion
exchange processes in plasma. The size and surface charge
of NPs play an important role in determining half-life in
circulation and biodistribution [5, 6]. Several examples of
ionic conjugates are reported in the literature. For example,
doxorubicin, methotrexate, paclitaxel, 5-fluorouracil, and
camptothecin have been loaded into micelles via both ionic
and hydrophobic interactions [7] or in dendrimers via non-
covalent entrapment [5].
In seeking charged Pt(II) drugs for testing ionic interac-
tions with suitable complementary carries, onemust be aware
that, among the platinum(II) amminechlorido derivatives,
the uncharged cisplatin is, in principle, the most active
antitumor agent, according to the SAR rules, defined by
Cleare and Hoeschele [8–10].
Conjugatesconsistingofpolymethylmetacrylate (PMMA)
core-shell NPs, bearing cationic (–NH
3
+) or anionic (–SO
3
−)
arms as vectors for [PtCl
3
(NH
3
)]− and [PtCl(NH
3
)
3
]+,
respectively, were reported by us [11, 12]. In the former case,
the in vivo antitumor effect of the conjugate was higher than
that of cisplatin in inhibiting B16 tumor growth in mice, in
spite of the fact that the free anionic drug showed modest
antiproliferative activity per se, as expected.
Recently, Lippard et al. demonstrated that monofunc-
tional platinum(II) complexes of general formula cis-
[Pt(Am)Cl(NH
3
)
2
]+ (Am = pyridine, 1, quinoline, 2, and
phenanthridine, 3) (Figure 1) display significant antitumor
properties. Their cellular response is different from that
of the classic cisplatin-like neutral drugs since they bind
to DNA in a monodentate fashion at the N7 position of
guanine residues and in the meantime intercalate the DNA
helix. The resulting adducts are able to inhibit transcription,
while the low distortion of the DNA significantly eludes
repair. In particular, phenanthriplatin, that is, (SP-4-3)-
diamminechlorido(phenanthridine)platinum(II) nitrate, 3,
exhibited greater activity than the approved drugs cisplatin
and oxaliplatin [13] on several tumor cell lines [13–18].
Dextrans are polysaccharides with a linear backbone of
𝛼(1,6)-linked D-glucopyranosyl residues. The use of dextran
as a vector for anticancer drugs has been explored since
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the ’70s and in many cases these conjugates displayed high
cellular uptake and good activity, combined with low toxicity
[19, 20]. Among charged polysaccharides, dextran sulfate,DS,
produced naturally by several bacteria or chemically with
reaction of dextran with chlorosulfonic acid, is well known
for its antiviral and anticoagulant properties. However, con-
cerns about the use of DS have been reported, because
it may cause anaphylactoid reactions and gastrointestinal
complaints [21].
A 500 kDa DS has been chosen as a proof of concept
that such negatively charged macromolecules are suitable for
DTD of cationic Pt complexes 1–3, since it has been reported
thatDS (especially at high𝑀
𝑟
) prolonged the circulation time
of the corresponding conjugates. Moreover, DS conjugates
with the anticancer drug doxorubicin (DOX) decreased
its removal from P-glycoprotein (P-gp), overexpressed in
multidrug-resistant cells, and 3, having a large heterocyclic
ligand, could be the substrate for P-gp driven efflux, in
contrast to cisplatin [22].
The ionic interaction between 1–3 and DS (Figure 1) is
here discussed, with the goal of defining the better experi-
mental conditions for the attaching and the releasing of the
cationic drugs to and from the anionic polymer, respectively.
The in vitro antiproliferative activity of the most promising
conjugate, namely, 3-DS, has been evaluated on a number of
human tumor cell lines. Any EPR effect (relevant for possible
DTD strategy) will be obviously appreciable only bymeans of
further in vivo experiments.
2. Materials and Methods
2.1. General Considerations. All chemicals (from Sigma-
Aldrich and Alfa Aesar-Johnson Matthey and Co., except
where otherwise indicated), including dextran sulfate (DS, as
sodium salt, from Leuconostoc spp.; average𝑀
𝑟
> 500,000),
were used without further purification. Compounds 1–3
were prepared according to published procedures [13] and
their purity was assessed by the usual analytical techniques
(elemental analysis, HPLC-MS, multinuclear NMR, etc.).
Hyphenated dynamic light scattering (DLS) at a fixed angle
(173∘) and 𝜁 potential experiments were carried out in
triplicate on aqueous solutions at 298K, by using a Zetasizer
NanoZS (Malvern, UK) operating in a particle size range
from 0.6 nm to 6 𝜇m and equipped by a He-Ne laser (𝜆 =
633 nm).
2.2. Synthesis of Pt-DS Conjugates. The conjugates of com-
plexes 1–3 were prepared by mixing 0.6mL of an aque-
ous mother solution of DS (10mgmL−1) with different
amounts of aqueous solutions of the Pt complexes (from
approx. 3 to 30mL, depending on the desired Pt/S ratio).
This procedure was chosen to limit the aggregation of the
conjugates. After 15min stirring, the mixture was dialyzed
against water (membrane cut-off = 14 kDa) for 24 h while the
external solution was freshly renewed several times. The Pt
loading ontoDSwas determined dissolving about 2mg of the
conjugates in 0.8mL of 70%w/w nitric acid, sonicated for 2 h
at 60∘C, and diluted with 1.0%w/v HNO
3
to determine sulfur
and platinum content by inductively coupled plasma-optical
emission spectroscopy (ICP-OES). A Spectro Genesis ICP-
OES spectrometer (Spectro Analytical Instruments, Kleve,
Germany) equipped with a crossflow nebulizer was used. In
order to quantify the Pt and S concentrations, the 299.797
and 180.731 nm lines were selected. Standard stock solutions
of 1000mg L−1 were diluted in 1.0%w/v nitric acid to prepare
calibration standards for both elements.
2.3. Pt Release from 3-DS. The stability of the phenan-
thriplatin-DS conjugates (3-DS) and the corresponding Pt
release were verified at 25∘C by dissolving them in 0.5x, 1x,
or 2x phosphate buffered saline, PBS (1x PBS = Na
2
HPO
4
8.1mM; KH
2
PO
4
1.76mM; NaCl, 137mM; KCl 2.7mM),
in a dialysis bag (membrane cut-off = 14 kDa). The Pt
released in the external buffer solution was monitored by
means of UV-visible spectroscopy (𝜆max for 3 = 251 nm, 𝜀 =
34433 ± 87M−1 cm−1). UV-visible spectrawere recordedwith
a JASCO V550 spectrophotometer.
2.4. Cell Culture and Growth Inhibition (IC50). Cisplatin,
free 3, and 3-DS were tested on the ovarian carcinoma
cell line A2780 and the colon carcinoma cell line HCT 116
(European Collection of Cell Cultures, UK). Additionally,
the above-said drug candidates were tested also on three
primary malignant pleural mesothelioma cancer cell lines,
derived from pleural effusion of patients with histologically
confirmed mesothelioma (i.e., BR95 epithelioid-, MM98
sarcomatoid-, and MG06 mixed/biphasic-phenotype) and
on the cisplatin-resistant cell line MM98R [23–25]. The
following media were used to culture the cells: RPMI 1640
(for A2780 cells), McCoy’s 5A (for HCT 116 cells), Ham’s
F10 (GIBCO, Invitrogen Life Science, San GiulianoMilanese,
Italy, for BR95 and MG06), and Dulbecco’s modified Eagle’s
medium (for MM98 and MM98R). In all cases, the media
were supplemented with L-glutamine (2mM), penicillin
100 IUmL−1, streptomycin (100mg L−1), and 10% fetal bovine
serum (FBS). Mother solutions of cisplatin and complex 3
were obtained by dissolving the compounds in a 0.9%w/v
NaCl aqueous solution brought to pH 3 with HCl (final
stock concentration 1mM). The dialyzed solution 3-DS was
used as a stock solution. The three solutions were diluted in
complete medium to the required concentration range and
the cells were challenged at 37∘C in a 5% CO
2
humidified
chamber with the compounds under study (72 h, continuous
treatment). A standard cell viability test (i.e., the resazurin
reduction assay) was used to assess the growth inhibition
of the compounds [26]. Details of the protocol have been
reported elsewhere [27].
2.5. Cellular Accumulation. The cellular accumulation exper-
iments were performed according to already published pro-
cedures [28]. Briefly, A2780 cells were treated with 10 𝜇M
concentrations of the compounds/formulations under inves-
tigations in 10mmPetri dishes or 175 cm2 flasks. After 4 h, the
cells were washed with PBS, detached from the Petri dishes
by using 0.05% Trypsin 1x + 2% EDTA (HyClone, Thermo
Fisher), and transferred into a glass tube. Centrifugation
and careful removal of the supernatant gave the cellular
pellets that were stored at −20∘C until mineralization. After
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Figure 2: Experimental versus theoretical Pt/S molar ratios for the
interaction between 1 (triangles), 2 (circles), and 3 (squares) with
DS.
defrosting, the cells were treated with 70% HNO
3
(for 1 h
at 60∘C in an ultrasonic bath) and the acid was diluted
to a final 1% concentration. The Pt content was measured
by inductively coupled plasma-mass spectrometry (ICP-MS,
Thermo Optek X Series 2). The concentration of Pt found in
cells after the treatmentwas normalized upon the cell number
and the cellular volume, in order to obtain the intracellular
Pt concentration. The ratio between the intra- and the
extracellular (in the culture medium) Pt concentration is
defined accumulation ratio, AR [29].
3. Results and Discussion
3.1. Synthesis of Pt-DS Conjugates, Pt Loading, and Pt-DS
Size. Complexes 1–3were synthesized according to literature
procedures. Briefly, upon reaction between cisplatin and
silver nitrate in DMF, the resulting cis-[PtCl(NH
3
)
2
NO
3
]
intermediate reacted with the corresponding heterocyclic
ligand to give the final product. The identity and the purity
of the complexes were checked by elemental analysis, HPLC-
MS, and multinuclear NMR that were in agreement with
previously published data [13].
The Pt-DS conjugates of complexes 1–3 were prepared by
adding the solution of each complex to an aqueous solution
of commercial 500 kDaDS. Importantly, the Pt concentration
should not exceed 1mM in the final solution, in order to
prevent quick and massive aggregation. After stirring for
15min, the solutions were dialyzed for 24 h against water.The
resulting solution can be used as it is or eventually lyophilized
to obtain a dried powder. Various Pt-DS samples were
synthesized and characterized according to their different
Pt/sulfate (evaluated as Pt/S) ratio by inductively coupled
plasma-optical emission spectroscopy (ICP-OES) (Figure 2).
The interaction of DS with 1 and 2 was quite similar
and only a small amount (max. 10%) of the Pt complex was
bound to the carrier even when Pt was added in 1 : 1 molar
ratio with respect to the sulfate groups present in DS. On
the contrary, a linear relationship between theoretical and
experimental Pt/S ratio is observed for the bulkier complex 3,
reaching up to the 50% Pt loaded. This is in contrast with the
occurrence of ionic interaction only, since the charge density
is in the order 1 > 2 > 3. These features seem to point out
that additional forces are involved in the formation of the
conjugate. In agreement with what was reported for DOX-
DS conjugates [30], beyond electrostatic interactions, 𝜋-𝜋
stacking between drug andDS, togetherwith some additional
hydrogen bonding, may also occur (see below for further
comments). In particular, 𝜋-𝜋 stacking can be significantly
more marked in the case of 3 with respect to the other
complexes, justifying its higher loading.
Since 3 shows higher loading than the others and, more-
over, it is the most cytotoxic agent of this class of cationic
complexes [13], the following study was focused on 3 only.
In this context, the conjugate containing the Pt/S final
molar ratio of 33 ± 2%, hereafter named 3-DS, showing
excellent water solubility, was used throughout (0.76mg of 3
per mg of nativeDS).
In order to verify the size of the above-said conjugate,
both a freshly dialyzed solution and a sample, obtained
after lyophilization and water redissolution, were analyzed
by dynamic light scattering (DLS). The lyophilized sample
showed a multimodal dimension distribution with the main
set having mean diameter of about 1280 nm. Thus, the
lyophilization of the sample favored the formation of larger
aggregates and, therefore, this procedure was discarded.
On the contrary, the freshly dialyzed solution exhibited
particles with mean diameter of about 120 nm (DS alone
in such experimental conditions showed mean diameter of
about 250 nm). The fact that the conjugate 3-DS has smaller
size than DS can be ascribed to remarkable interactions
between 3 andDS, which cause amore compact arrangement
in the conjugate.
The freshly dialyzed solution containing such conjugate,
hereafter named 3-DS, was used for the biological tests.
Noteworthily, NPs with diameter ranging from 50 to 150 nm
are ideally suitable for exploiting EPR effect [31].
DLS measurements, performed in water during 14 days
after synthesis (the time interval for total release of 3 from
3-DS; see below), indicated that the nanoparticle size was
maintained throughout, testifying the good stability of 3-
DS. Hyphenated 𝜁 potential measurements showed that
both DS and 3-DS exhibit negative values (in the range
−40 to −50mV) due to the remaining free sulfate groups,
thus explaining the stability of the suspension by virtue of
interparticle repulsion forces.
3.2. Pt Release from 3-DS. The stability in pseudobiological
conditions is an important feature for the investigated con-
jugate. Therefore, the behavior of 3-DS was studied at 25∘C
as a function of time in phosphate buffered saline (PBS) at
different ionic strengths, obtained from different dilutions of
themother PBS solution (Figure 3).The concentration of free
3 in solution was followed by UV-visible spectroscopy: its
release was directly correlated with the ionic strength of the
medium.
For all PBS concentrations, the corresponding curves
reached a sort of plateau after 10–15 h each with different
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Table 1: Antiproliferative activity (IC
50
values, 𝜇M) after 72 h continuous treatment and cellular accumulation (AR, 4 h, 10𝜇M) of cisplatin,
complex 3, and its conjugate 3-DS.
Complex IC50 (𝜇M) AR(A2780)A2780 HCT 116 BR95 MG06 MM98 MM98R
Cisplatin 0.46 ± 0.11 2.32 ± 0.35 6.2 ± 0.9 4.1 ± 1.5 3.2 ± 1 19.4 ± 2.8 (6.1) 0.62 ± 0.12
3 0.12 ± 0.02 0.76 ± 0.09 1.32 ± 0.02 0.72 ± 0.14 0.86 ± 0.12 2.09 ± 0.06 (2.4) 4.81 ± 1.08
3-DS 0.20 ± 0.04 1.19 ± 0.02 2.13 ± 0.29 1.03 ± 0.09 1.83 ± 0.11 3.46 ± 0.36 (1.9) 3.03 ± 0.57∗
Data are means ± SD of at least three independent experiments performed in triplicate. Data in brackets are the resistance factor RF = IC50 (MM98R)/IC50
(MM98). The AR value of 3-DS was compared to that of free 3 by means of the two-sample 𝑡-test (∗𝑝 < 0.5).
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Figure 3: Determination of the Pt released from 3-DS in 0.5x (black
squares), 1x (white circles), and 2x PBS (black triangles) solutions
(pH = 7.4), at different times. 𝐴 = absorbance of the solution at
different time points (𝜆max = 308 nm);𝐴max = theoretical absorbance
of the solution considering a complete release of the loaded Pt
complex.
residual loading, corresponding to about 50%, 40%, and 30%
of drug release, respectively. Then, the release of 3 from 3-
DS smoothly continued and was almost complete within two
weeks.
The observed behavior is similar to that reported
for DOX-DS conjugate, where the electrostatic interac-
tion between negatively charged DS and positively charged
doxorubicin is strongly salt-dependent. In the actual case,
increasing the ion strengths of the medium, the cations
(Na+ and K+) and anions (Cl− and HPO
4
2−), present in the
PBS buffer, compete for the electrostatic interaction with
negatively (DS) and positively (3) charged species, respec-
tively. Additional forces than ionic interactions should be
responsible for the slow release of the remaining 3, observed
on a longer time scale. Likely, these interactions consist of 𝜋-
𝜋 stacking between adjacent aromatic-structured molecules
of 3, forced at short distance by their initial amassing on
DS pivoted by electrostatic interactions. Moreover, hydrogen
bonding interactions, involving the N–H groups of ammonia
ligands and sulfate groups, may play also an important role,
in a fashion similar to that found between ammonia ligands
and phosphate groups in cisplatin-DNA adducts [32].
A similar scenario, associated with the presence of mul-
tiple interaction forces, was indeed observed for DOX-DS
[30].
3.3. Antiproliferative Activity and Cellular Accumulation.
Complex 3 and its conjugate 3-DS (freshly dialyzed) were
tested on two cell lines derived from common human tumors
(namely, ovarian A2780 and colon HCT 116 carcinomas)
and on human malignant pleural mesothelioma (MPM) cell
lines (namely, epithelioid BR95, mixed MG06, sarcomatoid
MM98, and sarcomatoid cisplatin-resistant MM98R). MPM
is a kind of tumor that is very difficult to treat: the cur-
rent gold-standard frontline chemotherapy approved by the
Food and Drug Administration (FDA) consists of cisplatin
combined with the antifolate pemetrexed [33]. New drugs
and tailored treatments are highly warranted to improve the
outcome of MPM patients. The results obtained with the
studied compounds are reported in Table 1. As expected, the
best results were observed on the cisplatin-sensitive A2780
cells. The good ability to bypass cisplatin resistance (RF) in
MM98R cell line of 3 is maintained by the conjugate 3-DS.
In general, both are more active than reference cisplatin,
but free 3 is slightly more active than 3-DS. The differences
observed for the free and conjugated form of 3 are related
at first instance to the incomplete release of 3 from 3-
DS conjugate within the time interval of the viability tests.
Moreover, the cellular Pt accumulation of the two forms of
3 must be considered (Table 1). In fact, a key parameter
in understanding the mechanism of action of a drug is the
evaluation of its intracellular accumulation, which is the
final balance between cellular influx and efflux [34]. This
parameter is here expressed as accumulation ratio (AR),
the ratio between the intracellular Pt concentration and the
extracellular (in the culture medium) Pt concentration at a
given time [35]. The AR values for 3, 3-DS, and cisplatin as
a reference metallodrug were measured on A2780 cells after
4 h of continuous treatment (Table 1).
The 3-DS conjugate shows slightly less intracellular Pt
accumulation than the free 3, albeit both are internalized
more efficiently than cisplatin. As a rule of thumb, posi-
tively charged NPs show higher uptake through endocytosis
pathways than negatively charged counterparts [36–38] and,
unfortunately, the 3-DS conjugate has an overall negative
𝜁 potential. In contrast, the cationic polymer bearing the
anionic [PtCl
3
(NH
3
)]− complex showed remarkable cellular
uptake, via highly efficient endocytosis of the conjugate due
to its residual positive charge [11].
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4. Conclusions
In this work, the active cationic Pt(II) complexes
[Pt(Am)Cl(NH
3
)
2
]+ (Am =pyridine, 1, quinoline, 2, and phe-
nanthridine, 3) were allowed to react with an anionic mac-
romolecular carrier, that is, dextran sulfateDS, forming con-
jugates mainly via electrostatic interactions.
Complex 3 showed the higher loading efficiency of the
series, and its conjugate 3-DS released a substantial part
of the active species 3 in the first 10–15 h depending on
the ionic strength of the medium. However, a fraction of 3
remains tightly bound toDS pointing out that different inter-
action forces, likely 𝜋-𝜋 stacking between adjacent aromatic-
structured molecules of 3, are overlapped to the electrostatic
attraction.
Free 3 and the conjugate 3-DS showed in all tumor cell
lines IC
50
values lower (i.e., higher antiproliferative activity)
than those of the reference metallodrug cisplatin and, impor-
tantly, were able to bypass acquired cisplatin resistance on
MM98R cells.
The slight lower in vitro antiproliferative activity of
conjugate 3-DSwith respect to free 3 is due to the incomplete
release of 3 from 3-DSwithin the time interval of the viability
tests and to the lower cellular accumulation of 3-DS.
Further in vivo tests will be necessary in order to appreci-
ate any EPR effect for 3-DS.
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